Key Drivers
- Very high liquidity
- Negligible leverage
- Persistent cash burn
AIAI Summary
Pharvaris has shifted from a discovery play to a near‑term, binary commercial catalyst—NDA (1H‑2026) and CHAPTER‑3 readout (3Q‑2026) will likely reprice the equity, but finite cash into 1H‑2027 and prior dilution history mean trial delays or mixed results will almost certainly force dilutive financing that materially compresses upside.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Very high liquidity
- •Negligible leverage
- •Persistent cash burn
PHVS has a very strong cash reserve and negligible debt but no revenue and sustained high operating/R&D burn that forces dilutive financing to fund operations.
Price Behavior
Key Price Behavior Insights:
- •Mild downtrend
- •Failed rebounds
- •Short-term consolidation
Over the last month the stock has drifted down roughly 7–8% to $26, with resistance near $28.39, support near $25.42, failed rebound attempts and moderate volatility indicating seller control despite recent short-term consolidation.
~7–8% decline from ~$28.10 (2026-02-20) to $26.00 with failed rebound peaks in early
Sentiment & News
Key News Insights:
- •Deucrictibant validation
- •Analyst price optimism
- •Institutional stake rise
March 2026 brought strong clinical validation for Pharvaris' deucrictibant—via AAAAI data, real-world outcomes and two Phase 2 Lancet Haematology publications—coupled with growing analyst optimism and a meaningful institutional stake increase.
These concurrent clinical successes and heightened investor engagement should improve PHVS's commercial credibility and could support upside in the stock as late‑stage data and partnering or funding discussions progress
Similar Companies in Healthcare
Other companies in the same sector with AI ratings